Cambridge Cognition Holdings order intake above expectations (Interview)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss interim results for the six months ended 30th June 2021. Matthew talks us through the highlights, explains the increase in sales orders of 74% to £8.6 million, the effect of a successful spin-out and venture financing of Monument Therapeutics, what the launch of NeuroVocalix™ which is now ready for clinical trials means for the company and what we can expect from the company going forward.

Cambridge Cognition Holdings is a world leading neuroscience technology company committed to enhancing global research, accelerating treatment development and improving patient outcomes in conditions affecting brain health by optimising the assessment of cognition.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition growth in revenue of 50% to £4.5 million

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a positive trading update for the six months ended 30 June 2021. The Company enjoyed a strong performance in the first half

Cambridge Cognition Holdings

Cambridge Cognition completes spin-out of Monument Therapeutics

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the completion of the spin-out of Monument Therapeutics Limited, a drug development company applying digital phenotyping to central nervous system disorders.

Cambridge Cognition Holdings

Cambridge Cognition secures new £2.2 million contract

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has been selected as the cognitive assessment partner for a large at-home study.  The contract is valued at £2.2 million with revenue expected